Cadrenal Therapeutics Inc
Company Profile
Business description
Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.
Contact
822 A1A North
Suite 306
Ponte VedraFL32082
USAT: +1 904 300-0701
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
5
Stocks News & Analysis
stocks
Australia’s largest gold miner downgraded on a falling gold price
stocks
Cheap ASX share pays a heavy price for NRL rights
stocks
The World Cup stock you’ve never heard of
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,003.00 | 6.60 | 0.07% |
| CAC 40 | 8,314.77 | 24.19 | -0.29% |
| DAX 40 | 25,029.03 | 38.06 | -0.15% |
| Dow JONES (US) | 52,637.01 | 149.60 | 0.29% |
| FTSE 100 | 10,495.06 | 2.23 | -0.02% |
| HKSE | 24,182.37 | 7.25 | 0.03% |
| NASDAQ | 26,281.61 | 74.72 | 0.29% |
| Nikkei 225 | 67,242.73 | 1,315.00 | -1.92% |
| NZX 50 Index | 13,723.20 | 62.47 | -0.45% |
| S&P 500 | 7,575.39 | 31.75 | 0.42% |
| S&P/ASX 200 | 8,808.50 | 11.70 | 0.13% |
| SSE Composite Index | 3,913.79 | 82.37 | -2.06% |